Key result
Novel oral anticoagulants are efficacious, safe, and less cumbersome alternatives to warfarin for the treatment and prevention of thrombosis.
Novel oral anticoagulants provide efficacious, safe, and more convenient alternatives to warfarin for the management of thromboembolic diseases.
May support preferring NOACs over warfarin for convenience in select patients; leaves open need for prospective validation in diverse populations.
For decades, warfarin, a Vitamin K antagonist, was the only oral anticoagulant available to physicians. However, over the last decade, newer agents with different mechanisms of action have become available for the treatment and prevention of thromboembolic events. Physicians must become familiar with the pharmacokinetics, mechanisms of action, indications, risks, and benefits of these agents to become comfortable using them in clinical practice. This review will serve to discuss these aspects of the novel non-Vitamin K oral anticoagulant agents.
No takes yet. Share an insight, caveat, or question.
Anklesaria et al. (2016) conducted an editorial in Thromboembolic events, atrial fibrillation, venous thromboembolism. Novel oral anticoagulants (NOACs) vs. Warfarin or low molecular weight heparin was evaluated. Novel oral anticoagulants are efficacious, safe, and less cumbersome alternatives to warfarin for the treatment and prevention of thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: